ロード中...
Rosuvastatin pharmacokinetics in Asian and White subjects wild-type for both OATP1B1 and BCRP under control and inhibited conditions
The FDA recommends rosuvastatin dosage reductions in Asian patients because pharmacokinetic studies have demonstrated an approximate two-fold increase in median exposure to rosuvastatin in Asian subjects when compared to Caucasian controls. Yet, no explanation for this ethnic difference has been con...
保存先:
| 出版年: | J Pharm Sci |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5675025/ https://ncbi.nlm.nih.gov/pubmed/28385543 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.xphs.2017.03.027 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|